# Preferences, attitudes and views regarding genetic newborn screening (gNBS) for rare diseases: a systematic review of the literature and synthesis from 2009 to 2022

**Authors:** Sylvia Martin, Gergana Kyosovska-Peshtenska, Jennifer Audi, Kaja Zarakowska, Åsa Grauman, Jorien Veldwijk, Brett Hauber, Joshua Coulter, Aileen Fürer, Alexandra Wagner, Aneta Piperkova, Edith Sky Gross, Ferdinand Knieling, Gulcin Gumus, Marek Zak, Maria Martinez-Fresno, Alicia Granados, Stefaan Sansen, Yuen Man, Janbernd Kirschner, Lucia Pia Bruno, Enrico Silvio Bertini, Silvia Ottombrino, Antonio Novelli, Emanuele Agolini, Sandra Courbier, Nicolas Garnier, Tsungai Jackson, Branimir Velinov, Jessie Dubief, Roman Raming, Christina Saier, Fernanda Fortunato, Vera Frankova, Mats Hansson

PMC · DOI: 10.1186/s13023-025-04179-0 · Orphanet Journal of Rare Diseases · 2026-01-08

## TL;DR

This paper reviews attitudes toward genetic newborn screening for rare diseases, finding general support but highlighting concerns about false results and communication issues.

## Contribution

A systematic review and synthesis of stakeholder attitudes toward genetic newborn screening for rare diseases from 2009 to 2022.

## Key findings

- The main perceived opportunities in gNBS include benefits of early intervention to reduce diagnostic odyssey.
- Key barriers include stress from false results, psychosocial implications, and communication misunderstandings.
- Most respondents expressed positive views, particularly regarding the actionability of screening.

## Abstract

Newborn screening (NBS) and its genetic version, genetic NBS (gNBS), are now used to identify a broad range of conditions, including metabolic, endocrine, and genetic disorders, leading to significant reductions in infant mortality and long-term complications. Advances in genomic technologies, particularly next-generation sequencing, have enhanced the ability to detect rare diseases early, using gNBS, improving long-term outcomes. The availability and scope of gNBS vary across countries, influenced by national policies and technological advancements. This systematic literature review aims to clarify the specific barriers, opportunities, and more general attitudes that stakeholders express about gNBS for rare diseases.

We extracted articles from 2010 to 2022. We followed the PRISMA guidelines and registered the review via PROSPERO (CRD42022297678). From an initial retrieval of 4519 records, two selection rounds resulted in a final list of 112 articles, which were assessed across different categories exploring various aspects of gNBS. The most important perceived opportunities in gNBS were the benefits of early intervention to reduce the burden of the diagnostic odyssey. The main identified barriers included three key codes: the stress and risk associated with false results and dealing with uncertainty (n = 25), the psychosocial implications (n = 26), and misunderstandings due to lack of education or communication. The majority of respondents expressed positive views, particularly regarding actionability.

The results indicate a generally favourable attitude toward newborn screening, with subtle variations in viewpoints. Our findings on these themes can specifically inform how final attitudes are shaped based on particular aspects.

The online version contains supplementary material available at 10.1186/s13023-025-04179-0.

## Full-text entities

- **Genes:** SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, ACADM (acyl-CoA dehydrogenase medium chain) [NCBI Gene 34] {aka ACAD1, MCAD, MCADH}
- **Diseases:** SCID (MESH:D016511), CF (MESH:D003550), depression (MESH:D003866), phenylketonuria (MESH:D010661), RDs (MESH:D035583), hypothyroidism (MESH:D007037), FRAXA (MESH:D005600), NBS (MESH:D006475), RD (MESH:D000077733), ataxia (MESH:D001259), diseases (MESH:D004194), prematurity (MESH:C536271), sickle cell disease (MESH:D000755), spinal muscular atrophy (MESH:D009134), gNBS (MESH:D006177), DMD (MESH:D020388), SCT (MESH:C535780), Anxiety (MESH:D001007), sickle cell trait or disease (MESH:D012805), Stress (MESH:D000079225), Krabbe disease (MESH:D007965), confusion (MESH:D003221), PD (MESH:D006009), MCAD (MESH:C536038), metabolic, endocrine, haematological, immune, cardiac, and pulmonary disorders (MESH:D004700), SCD (MESH:C536778), congenital hypothyroidism (MESH:D003409), LMIC (MESH:D010033), genetic diseases (MESH:D030342), hearing loss (MESH:D034381)
- **Chemicals:** gNBS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12836846/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12836846/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12836846/full.md

---
Source: https://tomesphere.com/paper/PMC12836846